| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $300,000 ) |
| | 2025 | 2025 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44AI188680 | A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance | 000 | 1 | NIH | 12/17/2024 | $300,000 |
| | 2025 | 2022 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HD102242 | Identification of glycosaminoglycans for newborn screening and therapeutic monitoring of mucopolysaccharidoses | 000 | 3 | NIH | 2/10/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,168,328 ) |
| | 2024 | 2024 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HL162151 | A Low Blood Volume Platform for Recurrent Anticoagulation and Kidney Monitoring during Continuous Renal Replacement Therapy in Critically Ill Children | 002 | 3 | NIH | 6/28/2024 | $948,080 |
| | 2024 | 2024 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HL169045 | A Near-Patient, Low Blood Volume Platform for Rapid Comprehensive Evaluation of Coagulation in Trauma Patients | 001 | 2 | NIH | 7/15/2024 | $998,891 |
| | 2024 | 2023 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HL140662 | Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection | 000 | 8 | NIH | 10/17/2023 | $0 |
| | 2024 | 2023 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HL162151 | A Low Blood Volume Platform for Recurrent Anticoagulation and Kidney Monitoring during Continuous Renal Replacement Therapy in Critically Ill Children | 001 | 2 | NIH | 6/7/2024 | $1 |
| | 2024 | 2023 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HL169045 | A Near-Patient, Low Blood Volume Platform for Rapid Comprehensive Evaluation of Coagulation in Trauma Patients | 000 | 1 | NIH | 7/9/2024 | $0 |
| | 2024 | 2022 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44AI157716 | Rapid Differential Diagnosis of COVID-19 and Common Respiratory Infections | 000 | 3 | NIH | 7/16/2024 | $0 |
| | 2024 | 2022 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HL162151 | A Low Blood Volume Platform for Recurrent Anticoagulation and Kidney Monitoring during Continuous Renal Replacement Therapy in Critically Ill Children | 000 | 1 | NIH | 6/7/2024 | -$1 |
| | 2024 | 2022 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HL125484 | Digital Microfluidics - Minimizing Blood Volume for Pediatric Coagulation Screening | 000 | 6 | NIH | 8/6/2024 | -$305,950 |
| | 2024 | 2021 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HL146016 | An Innovative Unbound Bilirubin Assay to Identify Bilirubin-Induced Neurological Dysfunction (BIND) Risk as Part of a Comprehensive and Novel Point-of-Care Newborn Screening Panel | 000 | 3 | NIH | 1/11/2024 | -$174,143 |
| | 2024 | 2021 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44DA050375 | A Novel Workflow to Screen for Illicit Drug Exposure in Newborns | 000 | 3 | NIH | 2/12/2024 | -$108,308 |
| | 2024 | 2021 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HD094543 | Feasibility and validation of an integrated newborn screening algorithm with targeted Next Generation Sequencing (tNGS) technology as part of a 2nd-tier test for Pompe and MPS I | 000 | 3 | NIH | 12/11/2023 | -$103,271 |
| | 2024 | 2020 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HD096981 | A Low Blood Volume Platform for Global Newborn Screening of Common, Treatable Conditions | 000 | 3 | NIH | 12/8/2023 | -$26,391 |
| | 2024 | 2020 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HD072853 | Multiplex Platform for Point-of-Care Newborn Screening of Hyperbilirubinemia | 000 | 7 | NIH | 10/12/2023 | -$60,580 |
|
| Issue Date FY: 2023 ( Subtotal = $1,717,805 ) |
| | 2023 | 2023 | BAEBIES INC | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HL169045 | A Near-Patient, Low Blood Volume Platform for Rapid Comprehensive Evaluation of Coagulation in Trauma Patients | 001 | 1 | NIH | 6/21/2023 | $0 |
| | 2023 | 2023 | BAEBIES INC | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HL169045 | A Near-Patient, Low Blood Volume Platform for Rapid Comprehensive Evaluation of Coagulation in Trauma Patients | 000 | 1 | NIH | 4/6/2023 | $299,999 |
| | 2023 | 2023 | BAEBIES INC | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HL162151 | A Low Blood Volume Platform for Recurrent Anticoagulation and Kidney Monitoring during Continuous Renal Replacement Therapy in Critically Ill Children | 000 | 2 | NIH | 6/9/2023 | $830,640 |
| | 2023 | 2023 | BAEBIES INC | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HL140662 | Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection | 000 | 8 | NIH | 8/30/2023 | $863,466 |
| | 2023 | 2020 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HD102242 | Identification of glycosaminoglycans for newborn screening and therapeutic monitoring of mucopolysaccharidoses | 000 | 1 | NIH | 2/2/2023 | -$127 |
| | 2023 | 2020 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HD095713 | A Comprehensive Newborn Screening Solution for Duchenne and Congenital Muscular Dystrophies | 002 | 3 | NIH | 6/5/2023 | -$96,184 |
| | 2023 | 2020 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HD095713 | A Comprehensive Newborn Screening Solution for Duchenne and Congenital Muscular Dystrophies | 001 | 3 | NIH | 6/5/2023 | $96,184 |
| | 2023 | 2020 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HD095713 | A Comprehensive Newborn Screening Solution for Duchenne and Congenital Muscular Dystrophies | 000 | 3 | NIH | 5/15/2023 | -$96,184 |
| | 2023 | 2020 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HD095225 | Near Patient Acute Kidney Injury Biomarker Analysis in Critically Ill Neonates | 000 | 3 | NIH | 3/14/2023 | -$63,155 |
| | 2023 | 2019 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HD093494 | Expanding thyroid testing in high risk newborns: total T3, free T4, TSH and TRAB | 000 | 3 | NIH | 3/14/2023 | -$64,430 |
| | 2023 | 2019 | BAEBIES, INC. | 25 ALEXANDRIA WAY | DURHAM | NC | 27703 | DURHAM | USA | R44HD092154 | Comprehensive, Near Patient Assessment of Severe Hypoglycemia in Newborns Using Low Blood Volume | 000 | 3 | NIH | 3/14/2023 | -$52,404 |
|
| Issue Date FY: 2022 ( Subtotal = $3,104,449 ) |
| | 2022 | 2022 | BAEBIES, INC. | 615 DAVIS DR STE 800 | MORRISVILLE | NC | 27560-6845 | WAKE | USA | R44AI157716 | Rapid Differential Diagnosis of COVID-19 and Common Respiratory Infections | 001 | 3 | NIH | 8/24/2022 | $253,737 |
| | 2022 | 2022 | BAEBIES, INC. | 615 DAVIS DR STE 800 | MORRISVILLE | NC | 27560-6845 | WAKE | USA | R44HD102242 | Identification of glycosaminoglycans for newborn screening and therapeutic monitoring of mucopolysaccharidoses | 000 | 3 | NIH | 9/7/2022 | $703,049 |
| | 2022 | 2022 | BAEBIES, INC. | 615 DAVIS DR STE 800 | MORRISVILLE | NC | 27560-6845 | WAKE | USA | R44HL125484 | Digital Microfluidics - Minimizing Blood Volume for Pediatric Coagulation Screening | 000 | 6 | NIH | 4/1/2022 | $995,038 |
| | 2022 | 2022 | BAEBIES, INC. | 615 DAVIS DR STE 800 | MORRISVILLE | NC | 27560-6845 | WAKE | USA | R44HL140662 | Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection | 000 | 7 | NIH | 3/25/2022 | $878,833 |
| | 2022 | 2022 | BAEBIES, INC. | 615 DAVIS DR STE 800 | MORRISVILLE | NC | 27560-6845 | WAKE | USA | R44HL162151 | A Low Blood Volume Platform for Recurrent Anticoagulation and Kidney Monitoring during Continuous Renal Replacement Therapy in Critically Ill Children | 000 | 1 | NIH | 5/23/2022 | $266,110 |
| | 2022 | 2021 | BAEBIES, INC. | 615 DAVIS DR STE 800 | MORRISVILLE | NC | 27560-6845 | WAKE | USA | R44AI157716 | Rapid Differential Diagnosis of COVID-19 and Common Respiratory Infections | 000 | 2 | NIH | 8/24/2022 | $0 |
| | 2022 | 2019 | BAEBIES, INC. | 615 DAVIS DR STE 800 | MORRISVILLE | NC | 27560-6845 | WAKE | USA | R44HD092154 | Comprehensive, Near Patient Assessment of Severe Hypoglycemia in Newborns Using Low Blood Volume | 000 | 3 | NIH | 11/8/2021 | $0 |
| | 2022 | 2019 | BAEBIES, INC. | 615 DAVIS DR STE 800 | MORRISVILLE | NC | 27560-6845 | WAKE | USA | R44HD093494 | Expanding thyroid testing in high risk newborns: total T3, free T4, TSH and TRAB | 000 | 3 | NIH | 2/4/2022 | $0 |
| | 2022 | 2018 | BAEBIES, INC. | 615 DAVIS DR STE 800 | MORRISVILLE | NC | 27560-6845 | WAKE | USA | R43HD094507 | A Rapid, Near Patient System for Small Blood Volume Testing of Ammonia, Glutamine and Glutamate to Support Recurrent Monitoring of Acute Neonatal Hyperammonemia | 000 | 1 | NIH | 9/26/2022 | $5,765 |
| | 2022 | 2018 | BAEBIES, INC. | 615 DAVIS DR STE 800 | MORRISVILLE | NC | 27560-6845 | WAKE | USA | R44HL140662 | Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection | 001 | 1 | NIH | 9/26/2022 | $649 |
| | 2022 | 2018 | BAEBIES, INC. | 615 DAVIS DR STE 800 | MORRISVILLE | NC | 27560-6845 | WAKE | USA | R44HD095713 | A Comprehensive Newborn Screening Solution for Duchenne and Congenital Muscular Dystrophies | 000 | 1 | NIH | 9/26/2022 | $1,267 |
|
| Issue Date FY: 2021 ( Subtotal = $6,208,004 ) (Continued on the next page) |
| | 2021 | 2021 | BAEBIES, INC. | 615 DAVIS DR STE 800 | DURHAM | NC | 27709 | DURHAM | USA | R44HL125484 | Digital Microfluidics - Minimizing Blood Volume for Pediatric Coagulation Screening | 000 | 5 | NIH | 3/23/2021 | $994,792 |
| | 2021 | 2021 | BAEBIES, INC. | 615 DAVIS DR STE 800 | DURHAM | NC | 27709 | DURHAM | USA | R44HL140662 | Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection | 001 | 5 | NIH | 6/2/2021 | $253,772 |
| | 2021 | 2021 | BAEBIES, INC. | 615 DAVIS DR STE 800 | DURHAM | NC | 27709 | DURHAM | USA | R44HL140662 | Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection | 000 | 6 | NIH | 4/30/2021 | $912,027 |
| | 2021 | 2021 | BAEBIES, INC. | 615 DAVIS DR STE 800 | DURHAM | NC | 27709 | DURHAM | USA | R44HL146016 | An Innovative Unbound Bilirubin Assay to Identify Bilirubin-Induced Neurological Dysfunction (BIND) Risk as Part of a Comprehensive and Novel Point-of-Care Newborn Screening Panel | 001 | 3 | NIH | 3/23/2021 | $681,054 |
| | 2021 | 2021 | BAEBIES, INC. | 615 DAVIS DR STE 800 | DURHAM | NC | 27709 | DURHAM | USA | R44AI157716 | Rapid Differential Diagnosis of COVID-19 and Common Respiratory Infections | 000 | 1 | NIH | 2/11/2021 | $278,148 |
| | 2021 | 2021 | BAEBIES, INC. | 615 DAVIS DR STE 800 | MORRISVILLE | NC | 27560-6845 | WAKE | USA | R44AI157716 | Rapid Differential Diagnosis of COVID-19 and Common Respiratory Infections | 001 | 2 | NIH | 9/20/2021 | $1,000,000 |
| | 2021 | 2021 | BAEBIES, INC. | 615 DAVIS DR STE 800 | DURHAM | NC | 27709 | DURHAM | USA | R44DA050375 | A Novel Workflow to Screen for Illicit Drug Exposure in Newborns | 002 | 3 | NIH | 7/26/2021 | $672,757 |
| | 2021 | 2021 | BAEBIES, INC. | 615 DAVIS DR STE 800 | DURHAM | NC | 27709 | DURHAM | USA | R44HD094543 | Feasibility and validation of an integrated newborn screening algorithm with targeted Next Generation Sequencing (tNGS) technology as part of a 2nd-tier test for Pompe and MPS I | 000 | 3 | NIH | 12/18/2020 | $793,462 |
|
